Escalating Incidence of Swine Flu to Boost H1N1 Vaccination Market


The H1N1 flu epidemic created a public health emergency in 2009. It also created an opportunity for vaccine manufacturers to exhibit that working with various initiatives, both private and government-held entities around the world, they could manufacture and distribute a vaccine for the virus strain which resulted in rapidly rising deaths worldwide.

Read Report Overview @

H1N1 influenza virus vaccine is used to prevent infection caused by the H1N1 influenza virus. The person affected by human influenza virus suffers from general illness such as cold, fever, sore throat, muscle pains, severe headache, coughing, weakness, and general discomfort. The epidemic caused in 1918 and 1919 due to this virus caused deaths of 50 to 100 million people worldwide. In India, nearly 31,000 people were affected and 1,900 were reported dead due to H1N1/ swine flu in 2015.

Vaccination is the only best way of treating flu caused by H1N1 influenza virus. There are two types of vaccines to treat swine flu depending on the nature of virus inserted. These include flu shot- contains inactivated virus and FluMist- contains live virus. Flu shot is inactivated vaccine containing a killed virus and injected in the arm muscle. Intramuscular vaccine or the flu shot costs less as compared to FluMist and hence caters to larger percent of population. The FluMist vaccine contains attenuated live virus and is given through nasal track. Though the FLuMist vaccine has limited customers, this is the most effective form of vaccine with fewer side effects.

Additionally, the rising geriatric population increases the risk of respiratory tract diseases, and immune deficient diseases, thus increasing the risk factor for acquiring H1N1 influenza. Moreover, increased research in the field of vaccine technologies and significant government support are driving this market. However, lack of awareness and absence of experienced medical professionals are restraining the growth of H1N1 vaccines market.

Request for Discount @

Some of the major players operating in the global H1N1 vaccination market are AstraZeneca plc, Medimmune, GlaxoSmithKline, Novartis, and Sanofi Pasteur. Baxter, Sinovac, Commonwealth Serum Laboratories, Zydus Cadila and Others.

Leave a Reply